Výsledky vyhledávání - "Huckriede, A.L.W."

Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol

Autor: Tan, N.H., Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Bogers, S., Geers, D., Zaeck, L.M., Koopmans, M.P.G., Dalm, V.A.S.H., Kootstra, N.A., Huckriede, A.L.W., Baarle, D. van, Lafeber, M., GeurtsvanKessel, C.H., Vries, R.D. de, Kuy, P.H.M. van der

Publikováno v: Frontiers in Immunology, 13:1067749. Frontiers Media S.A.
Frontiers in immunology, 13:1067749. Frontiers Media S.A.
Frontiers in Immunology, 13. FRONTIERS MEDIA SA
Frontiers in Immunology, 13:1067749. Frontiers Media SA

Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over tim

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1ba8b0447a41a51477eae24df2dd616
https://pure.eur.nl/en/publications/fbbf77cd-2cb1-4911-aee3-20f7f6c80249

Zobrazit plný text záznamu

Durability of immune responses after boosting in Ad26.COV2.S-primed healthcare workers

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3). Oxford University Press
Clinical Infectious Diseases, 76(3), e533-e536. OXFORD UNIV PRESS INC
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 76(3):ciac495, e533-e536. Oxford University Press
Clinical infectious diseases, 76(3), e533-e536. Oxford University Press

The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2–specific binding antibodies, neutralizing antibodies, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f28486eec836495dfd683d7e47c56c68
https://doi.org/10.1093/cid/ciac495

Zobrazit plný text záznamu

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Autor: Sablerolles, R.S.G., Rietdijk, W.J.R., Goorhuis, A., Postma, D.F., Visser, L.G., Geers, D., Schmitz, K.S., Garrido, H.M.G., Koopmans, M.P.G., Dalm, V.A.S.H., Kootstra, N.A., Huckriede, A.L.W., Lafeber, M., Baarle, D. van, GeurtsvanKessel, C.H., Vries, R.D. de, Kuy, P.H.M. van der, SWITCH Res Grp

Publikováno v: New England Journal of Medicine, 386(10), 951-963. Massachussetts Medical Society
The New England journal of medicine, 386(10), 951-963. MASSACHUSETTS MEDICAL SOC
New England journal of medicine, 386(10), 951-963. Massachussetts Medical Society
The New England Journal of Medicine
New England Journal of Medicine, 386, 951-963. MASSACHUSETTS MEDICAL SOC

BACKGROUND: The Ad26.COV2.S vaccine, which was approved as a single-shot immunization regimen, has been shown to be effective against severe coronavirus disease 2019. However, this vaccine induces lower severe acute respiratory syndrome coronavirus 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c533e6a2e396ec700dfcc8c219db189
http://hdl.handle.net/10029/625622

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání